DK4126932T3 - Anti-bk-virusantistofmolekyler - Google Patents

Anti-bk-virusantistofmolekyler Download PDF

Info

Publication number
DK4126932T3
DK4126932T3 DK21730952.5T DK21730952T DK4126932T3 DK 4126932 T3 DK4126932 T3 DK 4126932T3 DK 21730952 T DK21730952 T DK 21730952T DK 4126932 T3 DK4126932 T3 DK 4126932T3
Authority
DK
Denmark
Prior art keywords
virus antibodies
antibodies molecules
molecules
virus
antibodies
Prior art date
Application number
DK21730952.5T
Other languages
English (en)
Inventor
Marcel Weber
Simone Schmitt
Christoph Esslinger
Thomas Schachtner
Uyen Huynh-Do
Maurizio Provenzano
Original Assignee
Memo Therapeutics Ag
Univ Bern
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memo Therapeutics Ag, Univ Bern, Univ Zuerich filed Critical Memo Therapeutics Ag
Application granted granted Critical
Publication of DK4126932T3 publication Critical patent/DK4126932T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/025Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
DK21730952.5T 2020-06-09 2021-06-09 Anti-bk-virusantistofmolekyler DK4126932T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20179041 2020-06-09
EP20179044 2020-06-09
PCT/EP2021/065462 WO2021250097A1 (en) 2020-06-09 2021-06-09 Anti-bk virus antibody molecules

Publications (1)

Publication Number Publication Date
DK4126932T3 true DK4126932T3 (da) 2024-01-22

Family

ID=76325565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21730952.5T DK4126932T3 (da) 2020-06-09 2021-06-09 Anti-bk-virusantistofmolekyler

Country Status (23)

Country Link
US (2) US11919943B2 (da)
EP (2) EP4126932B1 (da)
JP (1) JP2023528828A (da)
KR (1) KR20230035578A (da)
CN (1) CN115776988A (da)
AU (1) AU2021288986A1 (da)
BR (1) BR112022024288A2 (da)
CA (1) CA3181750A1 (da)
CL (1) CL2022003491A1 (da)
CO (1) CO2023000070A2 (da)
DK (1) DK4126932T3 (da)
FI (1) FI4126932T3 (da)
HR (1) HRP20231739T1 (da)
IL (1) IL298803A (da)
LT (1) LT4126932T (da)
MX (1) MX2022015071A (da)
PE (1) PE20231444A1 (da)
PL (1) PL4126932T3 (da)
PT (1) PT4126932T (da)
RS (1) RS65172B1 (da)
SI (1) SI4126932T1 (da)
WO (1) WO2021250097A1 (da)
ZA (1) ZA202212136B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4126932T (pt) 2020-06-09 2024-01-18 Univ Zuerich Moléculas de anticorpo anti-vírus b
WO2023175171A1 (en) * 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896824A1 (en) * 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
CN111417651B (zh) * 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
PT4126932T (pt) 2020-06-09 2024-01-18 Univ Zuerich Moléculas de anticorpo anti-vírus b

Also Published As

Publication number Publication date
US11919943B2 (en) 2024-03-05
BR112022024288A2 (pt) 2023-01-31
CA3181750A1 (en) 2021-12-16
ZA202212136B (en) 2024-02-28
JP2023528828A (ja) 2023-07-06
EP4327883A3 (en) 2024-05-22
SI4126932T1 (sl) 2024-03-29
RS65172B1 (sr) 2024-03-29
PE20231444A1 (es) 2023-09-14
PT4126932T (pt) 2024-01-18
WO2021250097A1 (en) 2021-12-16
AU2021288986A1 (en) 2022-12-15
CL2022003491A1 (es) 2023-08-11
IL298803A (en) 2023-02-01
LT4126932T (lt) 2024-02-12
PL4126932T3 (pl) 2024-04-22
EP4126932A1 (en) 2023-02-08
CN115776988A (zh) 2023-03-10
US20230192816A1 (en) 2023-06-22
CO2023000070A2 (es) 2023-02-16
HRP20231739T1 (hr) 2024-03-15
EP4327883A2 (en) 2024-02-28
KR20230035578A (ko) 2023-03-14
MX2022015071A (es) 2023-02-27
EP4126932B1 (en) 2023-11-15
FI4126932T3 (fi) 2024-01-18
US20240132575A1 (en) 2024-04-25

Similar Documents

Publication Publication Date Title
DK3645570T3 (da) VISTA-antigenbindende molekyler
MA53434A (fr) Anticorps anti-tigit
MA53616A (fr) Protéines bispécifiques modifiées
MA52884A (fr) Anticorps anti-il-11
DK3645571T3 (da) Her3-antigen-bindende molekyler
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
DK3606961T3 (da) Garp-tgf-beta-antistoffer
DK4126932T3 (da) Anti-bk-virusantistofmolekyler
DK3387132T3 (da) Aptamerer, nukleinsyremolekyler, polynukleotider, syntetiske antistofsammensætninger til påvisning af prrs-vira og behandling af prrs-virusinfektion
BR112017025496A2 (pt) Moléculas de ligação neutralizantes anti- influenza e usos das mesmas
MA55516A (fr) Agents de dégradation, à petites molécules, de stat3
MA56466A (fr) Anticorps anti-epha4
IL292799A (en) Antibodies against siglec-9
IT201700045556A1 (it) Cappa aspirante da laboratorio
KR20220016865A9 (ko) 항원 결합 분자, 약학 조성물, 및 방법
DK3671200T3 (da) Ce-western-applikationer til udvikling af antistof
MA56394A (fr) Anticorps anti-angpt2
CY2023014I1 (el) Αντι il-36r αντισωματα
ES1251079Y (es) Equipo portátil identificador de virus
UA43602S (uk) Вібраційна машина-віброплита
CY2021027I2 (el) Σκευασματα αντισωματων anti-cd20
JP1720612S (ja) ファイル
JP1720706S (ja) ファイル
JP1720611S (ja) ファイル
JP1717204S (ja) ファイル